Grundläggande statistik
| CIK | 1421204 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Rebus Holdings, Inc.
SEC Filings (Chronological Order)
Denna sida innehåller en komplett, kronologisk lista över SEC-arkiveringar, exklusive ägande-arkiveringar som vi tillhandahåller på andra ställen.
| August 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2023 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 000-55331 REBUS HOLDINGS, INC. (Exact name of registra |
|
| August 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 SEC FILE NUMBER 000-55331 CUSIP NUMBER NOTIFICATION OF LATE FILING 75619J 103 (Check one): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended: June 30, 2023 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transi |
|
| May 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2023 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 000-55331 REBUS HOLDINGS, INC. (Exact name of registr |
|
| March 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 000-55331 REBUS HOLDING |
|
| November 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2022 Or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 000-55331 REBUS HOLDINGS, INC. (Exact name of reg |
|
| November 16, 2022 |
Changes in Registrant's Certifying Accountant UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 16, 2022 (November 9, 2022) Rebus Holdings, Inc. (Exact name of registrant as specified in Charter) Delaware 0001421204 000-55331 20-0438951 (State or other jurisdiction of i |
|
| November 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NT 10-Q 1 rebusholdingsnt10q.htm NT 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 SEC File Number 000-55331 NOTIFICATION OF LATE FILING (Check One): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended: September 30, 2022 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report |
|
| October 13, 2022 |
Letter to SEC from Liggett & Webb P.A. dated October 13, 2022 Exhibit 16.1 October 13, 2022 Securities and Exchange Commission 100 F Street N.E. Washington, D.C. 20549 RE: Rebus Holdings, Inc. File Ref No: 000-55331 We have read the statements of Rebus Holdings, Inc., pertaining to our firm included under Item 4.01 of Form 8-K dated October 10, 2022 and agree with such statements as they pertain to our firm. We have read Item 4.01, captioned ?Changes in Comp |
|
| October 13, 2022 |
Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 13, 2022 (October 10, 2022) Rebus Holdings, Inc. (Exact name of registrant as specified in Charter) 000-55331 Delaware 0001421204 20-0438951 (State or other jurisdiction of in |
|
| August 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2022 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 000-55331 REBUS HOLDINGS, INC. (Exact name of registra |
|
| May 13, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2022 Or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 000-55331 REBUS HOLDINGS, INC. (Exact name of registr |
|
| March 31, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 000-55331 REBUS HOLDING |
|
| March 31, 2022 |
List of Subsidiaries of Registrant Exhibit 21.01 List of Subsidiaries of Rebus Holdings, Inc. ? Inspyr Therapeutics, Inc., ? Ridgeway Therapeutics, Inc. (CA Corporation), and ? Lewis and Clark Pharmaceuticals, Inc. |
|
| December 9, 2021 |
Rule 424(b)(3) Registration No. 333-255618 PROSPECTUS 5,806,864 Shares Common Stock This prospectus relates to the resale of 5,806,864 shares of our common stock, by the selling stockholder(s) identified in the selling stockholders tables beginning on page 18 of this prospectus (?Selling Stockholder(s)?). We will not receive any proceeds from the sale of these shares by the Selling Stockholders. T |
|
| December 8, 2021 |
CORRESP 1 filename1.htm REBUS HOLDINGS, INC. December 8, 2021 Tim Buchmiller Staff Attorney Office of Life Sciences Division of Corporation Finance United States Securities and Exchange Commission Washington, DC 20549 RE: Rebus Holdings, Inc. Registration Statement on Form S-1 Filed December 3, 2021 File No. 333-255618 Dear Mr. Buchmiller: Pursuant to Rule 461 under the Securities Act of 1933, as |
|
| December 3, 2021 |
Consent of Independent Registered Certified Public Accountant Exhibit 23.01 CONSENT OF INDEPENDENT REGISTERED CERTIFIED PUBLIC ACCOUNTANTS We hereby consent to the use in this Pre-effective Amendment No.1 to Form S-1 Registration Statement of our report dated March 31, 2021, except for footnote 3 “Reverse Stock Split,”, footnote 9 “Reverse Stock Split” and footnote 15 “Reverse Stock Split,” as to which the date is December 3, 2021, relating to the December 3 |
|
| December 3, 2021 |
List of Subsidiaries of Registrant Exhibit 21.01 List of Subsidiaries of Rebus Holdings, Inc. ? Lewis and Clark Pharmaceuticals, Inc. ? Inspyr Therapeutics, Inc. |
|
| December 3, 2021 |
Exhibit 5.01 SILVESTRE LAW GROUP, P.C. 2629 Townsgate Road #215 Westlake Village, CA 91361 (818) 597-7552 Fax (805) 553-9783 December 3, 2021 Rebus Holdings, Inc. 2629 Townsgate Road #215 Westlake Village, CA 91361 Ladies and Gentlemen: We have acted as counsel to Rebus Holdings, Inc., a Delaware corporation (the “Company”) in connection with the Pre-effective Amendment No. 1 to the Registration S |
|
| December 3, 2021 |
As filed with the Securities and Exchange Commission on December 3, 2021 As filed with the Securities and Exchange Commission on December 3, 2021 Registration No. |
|
| November 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2021 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 000-55331 REBUS HOLDINGS, INC. (Exact name of reg |
|
| November 12, 2021 |
Rebus Holdings Bylaws dated November 11, 2021 EX-3.16(II) 2 rebusholdingsex3-16ii.htm EXHIBIT 3.16(II) Exhibit 3.16(ii) AMENDED AND RESTATED BYLAWS OF REBUS HOLDINGS, INC. (Amended and Restated on November 11, 2021) BYLAWS OF REBUS HOLDINGS, INC. ARTICLE I CORPORATE OFFICES 1.1 REGISTERED OFFICE. The registered office of Rebus Holdings, Inc. shall be fixed in the corporation’s certificate of incorporation, as the same may be amended and/or re |
|
| October 12, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 12, 2021 Inspyr Therapeutics, Inc. (Exact name of registrant as specified in Charter) Delaware 0001421204 000-55331 20-0438951 (State or other jurisdiction of incorporation or |
|
| October 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 12, 2021 Inspyr Therapeutics, Inc. (Exact name of registrant as specified in Charter) Delaware 0001421204 000-55331 20-0438951 (State or other jurisdiction |
|
| October 12, 2021 |
Exhibit 99.01 INSPYR THERAPEUTICS Inspyr Therapeutics Announces New Holding Company Structure and Reverse Stock Split WESTLAKE VILLAGE, CA, October 12, 2021 (GLOBE NEWSWIRE) ? Inspyr Therapeutics, Inc. (?Inspyr?) is announcing (i) a 1-for-75 reverse stock split of its common stock and (ii) a holding company restructuring whereby Rebus Holdings, Inc. (?Rebus?), a newly created entity will serve as |
|
| October 5, 2021 |
Amended and Restated Bylaws of Inspyr Therapeutics, Inc. EX-3.03(II) 5 inspyrtherapex3-03ii.htm EXHIBIT 3.03(II) Exhibit 3.03(ii) AMENDED AND RESTATED BYLAWS OF INSPYR THERAPEUTICS, INC. (October 5, 2021) ARTICLE I. NAME OF CORPORATION The name of the corporation is Inspyr Therapeutics, Inc. ARTICLE II. OFFICES SECTION 1. The principal office of the corporation shall be fixed in the corporation’s certificate of incorporation, as the same may be amended |
|
| October 5, 2021 |
Certificate of Merger between Inspyr Therapeutics, Inc. and Rebus Sub, Inc. Exhibit 3.02(i) CERTIFICATE OF MERGER OF REBUS SUB, INC., WITH AND INTO INSPYR THERAPEUTICS, INC. Pursuant to Section 251 of the General Corporation Law of the State of Delaware (?DGCL?), the undersigned corporation hereby certifies that: FIRST: The name and state of incorporation of each of the constituent corporations to the merger are as follows: Name State of Incorporation Inspyr Therapeutics, |
|
| October 5, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 4, 2021 (September 28, 2021) Inspyr Therapeutics, Inc. (Exact name of registrant as specified in Charter) Delaware 000-55331 20-0438951 (State or other jurisdiction of incorpo |
|
| October 5, 2021 |
Exhibit 3.01(i) AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF INSPYR THERAPEUTICS, INC. a Delaware Corporation The undersigned does hereby certify on behalf of Inspyr Therapeutics, Inc. (the ?Corporation?), a corporation organized and existing under the Delaware General Corporation Law, as follows: FIRST: That the undersigned is the duly elected and acting Chief Executive Officer of the Cor |
|
| October 5, 2021 |
Exhibit 2.01 AGREEMENT AND PLAN OF MERGER AGREEMENT AND PLAN OF MERGER (this ?Agreement?), dated as of September 28, 2021, by and among Inspyr Therapeutics, Inc., a Delaware corporation (the ?Company?), Rebus Holdings, Inc., a Delaware corporation and a direct wholly owned subsidiary of the Company (?Rebus?), and Rebus Sub, Inc., a Delaware corporation and a direct wholly owned subsidiary of Rebus |
|
| September 3, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: ? Preliminary Information Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) ? Definitive Information Statement Inspyr Therapeutics, Inc. (Name of R |
|
| August 25, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: ☒ Preliminary Information Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) ☐ Definitive Information Statement Inspyr Therapeutics, Inc. (Name of R |
|
| August 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2021 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 000-55331 INSPYR THERAPEUTICS, INC. (Exact name of reg |
|
| June 21, 2021 |
Form of Convertible Debenture for June 2021 Private Placement Exhibit 10.01 NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGI |
|
| June 21, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 21, 2021 (June 16, 2021) Inspyr Therapeutics, Inc. (Exact name of registrant as specified in Charter) Delaware 0001421204 20-0438951 (State or other jurisdiction of incorporation |
|
| May 17, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2021 Or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 000-55331 INSPYR THERAPEUTICS, INC. (Exact name of re |
|
| April 29, 2021 |
As filed with the Securities and Exchange Commission on April 29, 2021 Registration No. |
|
| April 29, 2021 |
Consent of Independent Registered Certified Public Accountant Exhibit 23.01 CONSENT OF INDEPENDENT REGISTERED CERTIFIED PUBLIC ACCOUNTANTS We hereby consent to the use in this Form S-1 Registration Statement of our report dated March 31, 2021, relating to the December 31, 2020 and 2019 consolidated financial statements of Inspyr Therapeutics, Inc., which appear in this Registration Statement and related Prospectus. Our report includes an explanatory paragrap |
|
| April 29, 2021 |
Exhibit 5.01 SILVESTRE LAW GROUP, P.C. 2629 Townsgate Road #215 Westlake Village, CA 91361 (818) 597-7552 Fax (805) 553-9783 April 29, 2021 Inspyr Therapeutics, Inc. 2629 Townsgate Road #215 Westlake Village, CA 91361 Ladies and Gentlemen: We have acted as counsel to Inspyr Therapeutics, Inc., a Delaware corporation (the “Company”) in connection with the Registration Statement on Form S-1 (the “Re |
|
| April 1, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 1, 2021 (March 31, 2021) Inspyr Therapeutics, Inc. (Exact name of registrant as specified in Charter) Delaware 0001421204 20-0438951 (State or other jurisdiction of incorporatio |
|
| April 1, 2021 |
Exhibit 99.01 INSPYR THERAPEUTICS Inspyr Therapeutics Reports Financial Results and Business Update For Full Year 2020 ? Implements new corporate strategy to focus on precision therapeutics for the treatment of cancer ? Strengthens pipeline by acquiring a proprietary portfolio of novel adenosine immuno-modulator compounds ? Lead asset, RT-AR001, pre-IND filing is on track for the first half of 202 |
|
| March 31, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 000-55331 INSPYR THERAP |
|
| January 12, 2021 |
Exhibit 99.01 INSPYR THERAPEUTICS Inspyr Therapeutics Secures $500,000 to Support the Development of its Adenosine Pipeline ● Proceeds support the development of lead asset, RT-AR001, an adenosine receptor antagonist ● Funds were secured from an existing institutional investor Westlake Village, CA, January 12, 2021 – Inspyr Therapeutics, Inc. (OTC: NSPX), a pharmaceutical company focused on the re |
|
| January 12, 2021 |
Form of Convertible Debenture for January 2021 Private Placement Exhibit 10.01 NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGI |
|
| January 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 12, 2021 Inspyr Therapeutics, Inc. (Exact name of registrant as specified in Charter) Delaware 0001421204 20-0438951 (State or other jurisdiction of incorporation or organizat |
|
| November 27, 2020 |
Amended and Restated Certificate of Incorporation EX-3.01(I) 2 inspyrtherapeuticsex3-01i.htm EXHIBIT 3.01(I) Exhibit 3.01(i) AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF INSPYR THERAPEUTICS, INC. ARTICLE I The name of this Corporation is Inspyr Therapeutics, Inc. (this “Corporation”). ARTICLE II The address of the registered office of the corporation in the State of Delaware is 850 New Burton Road, Suite 201, Dover, Delaware, county of Ke |
|
| November 27, 2020 |
Conversion Price Adjustment Agreement Exhibit 10.01 CONVERSION PRICE ADJUSTMENT AGREEMENT This conversion price adjustment agreement (“Agreement”) dated as of November 25, 2020 is by and among Sabby Healthcare Master Fund, Ltd., Sabby Volatility Warrant Master Fund, Ltd. (collectively, “Sabby”) and Inspyr Therapeutics, Inc., a Delaware corporation (the “Company”). Any terms not specifically defined herein shall have the definition asc |
|
| November 27, 2020 |
8-K 1 inspyrtherapeutics8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 27, 2020 (November 25, 2020) Inspyr Therapeutics, Inc. (Exact name of registrant as specified in Charter) Delaware 0001421204 20-0438951 (S |
|
| November 20, 2020 |
Quarterly Report - QUARTERLY REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C.20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2020 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 000-55331 INSPYR THERAPEUTICS, INC. (Exact name of |
|
| November 16, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 SEC File Number 000-55331 NOTIFICATION OF LATE FILING (Check One): ? Form 10-K ? Form 20-F ? Form 11-K ? Form 10-Q ? Form 10-D ? Form N-SAR ? Form N-CSR For Period Ended: September 30, 2020 ? Transition Report on Form 10-K ? Transition Report on Form 20-F ? Transition Report on Form 11-K ? Transition Report on Form |
|
| November 4, 2020 |
- DEFINITIVE INFORMATION STATEMENT DEF 14C 1 ea129314-def14cinspyrtherap.htm DEFINITIVE INFORMATION STATEMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: ☐ Preliminary Information Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)( |
|
| November 2, 2020 |
SILVESTRE LAW GROUP, P.C. 2629 Townsgate Road, Suite 215 Westlake Village, CA 91361 (818) 597-7552 Fax (805) 553-9783 November 2, 2020 Division of Corporation Finance Office of Life Sciences United States Securities and Exchange Commission Washington, DC 20549 RE: Inspyr Therapeutics, Inc. Preliminary Information Statement on Schedule 14C Filed October 16, 2020 File No. 000-55331 Dear Ladies and G |
|
| November 2, 2020 |
- AMENDMENT NO. 1 TO PRELIMINARY INFORMATION STATEMENT PRER14C 1 ea129247-prer14cinspyrther.htm AMENDMENT NO. 1 TO PRELIMINARY INFORMATION STATEMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: ☒ Preliminary Information Statement ☐ Confidential, for Use of the Commission O |
|
| October 29, 2020 |
Form of Debenture for October 2020 Private Placement Exhibit 10.01 NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGI |
|
| October 29, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 29, 2020 (October 23, 2020) Inspyr Therapeutics, Inc. (Exact name of registrant as specified in Charter) Delaware 0001421204 20-0438951 (State or other jurisdiction of incorpo |
|
| October 16, 2020 |
- PRELIMINARY INFORMATION STATEMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: ☒ Preliminary Information Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) ☐ Definitive Information Statement Inspyr Therapeutics, Inc. (Name of R |
|
| October 15, 2020 |
- PRELIMINARY INFORMATION STATEMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: ☒ Preliminary Information Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) ☐ Definitive Information Statement Inspyr Therapeutics, Inc. (Name of R |
|
| October 8, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 8, 2020 (October 5, 2020) Inspyr Therapeutics, Inc. (Exact name of registrant as specified in Charter) Delaware 0001421204 20-0438951 (State or other jurisdiction of incorpora |
|
| October 8, 2020 |
Termination of Licensing Agreement with Ridgeway Therapeutics, Inc. dated October 5, 2020 Exhibit 10.01 October 5, 2020 Inspyr Therapeutics, Inc. 2629 Townsgate Road #215 Westlake Village, CA 91361 (818) 597-7552 [email protected] Ridgeway Therapeutics, Inc. [Address] [Address] [Email] Dear Colin Hislop, Inspyr Therapeutics, Inc. (“Inspyr”) is providing this letter agreement (“Letter Agreement”) to Ridgeway Therapeutics, Inc. (“Ridgeway”) in connection with the License Agreem |
|
| October 8, 2020 |
EX-99.01 4 ea127966ex99-01inspyrtherap.htm PRESS RELEASE DATED OCTOBER 8, 2020 Exhibit 99.01 Inspyr Therapeutics acquires a novel immuno-onoclogy precision targeting platform for the treatment of cancer Preclinical data demonstrated delayed tumor growth, reduces metastases and anti-tumor immune response Westlake Village, CA (October 8, 2020) – Inspyr Therapeutics, Inc. (OTC/PINK: NSPX), announces |
|
| October 8, 2020 |
Exhibit 3.01(i) INSPYR THERAPEUTICS, inc. CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES F 0% CONVERTIBLE PREFERRED STOCK PURSUANT TO SECTION 151(g) OF THE Delaware GENERAL CORPORATION LAW The undersigned, Michael Cain does hereby certify that: 1. He is the President of Inspyr Therapeutics, Inc., a Delaware corporation (the “Corporation”). 2. The Corporation is authori |
|
| August 14, 2020 |
Quarterly Report - QUARTERLY REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C.20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2020 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 000-55331 INSPYR THERAPEUTICS, INC. (Exact name of regi |
|
| July 6, 2020 |
Quarterly Report - QUARTERLY REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C.20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2020 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 000-55331 INSPYR THERAPEUTICS, INC. (Exact name of reg |
|
| July 2, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 SEC File Number 000-55331 NOTIFICATION OF LATE FILING (Check One): ¨ Form 10-K ¨ Form 20-F ¨ Form 11-K x Form 10-Q ¨ Form 10-D ¨ Form N-SAR ¨ Form N-CSR For Period Ended: March 31, 2020 ¨ Transition Report on Form 10-K ¨ Transition Report on Form 20-F ¨ Transition Report on Form 11-K ¨ Transition Report on Form 10- |
|
| June 29, 2020 |
8-K 1 ea123552-8kinspyrtherape.htm CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 29, 2020 (June 26, 2020) Inspyr Therapeutics, Inc. (Exact name of registrant as specified in Charter) Delaware 0001421204 20-043 |
|
| June 29, 2020 |
Amended and Restated Certificate of Incorporation, effective June 26, 2020 Exhibit 3.01(i) AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF INSPYR THERAPEUTICS, INC. a Delaware Corporation The undersigned does hereby certify on behalf of Inspyr Therapeutics, Inc. (the “Corporation”), a corporation organized and existing under the Delaware General Corporation Law, as follows: FIRST: That the undersigned is the duly elected and acting Chief Executive Officer of the Cor |
|
| May 27, 2020 |
- DEFINITIVE INFORMATION STATEMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: ☐ Preliminary Information Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) ☒ Definitive Information Statement Inspyr Therapeutics, Inc. (Name of R |
|
| May 15, 2020 |
- PRELIMINARY INFORMATION STATEMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: ☒ Preliminary Information Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) ☐ Definitive Information Statement Inspyr Therapeutics, Inc. (Name of R |
|
| May 14, 2020 |
10-K 1 f10k2019inspyrthera.htm ANNUAL REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . C |
|
| May 14, 2020 |
Form of Securities Purchase Agreement for May 2020 Preferred Stock Offering Exhibit 10.25 May 2, 2020 Inspyr Therapeutics, Inc. 31200 Via Colinas #200 Westlake Village, CA 91362 Re: Inspyr Therapeutics, Inc. - Subscription for Shares of Series E Preferred Stock Ladies and Gentlemen: The undersigned hereby acknowledges and agrees to the following: 1. The undersigned hereby subscribes for shares totaling an aggregate consideration of $5,000 of Series E Convertible Preferred |
|
| May 14, 2020 |
Exhibit 3.10(i) INSPYR THERAPEUTICS, inc. CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES E 0% CONVERTIBLE PREFERRED STOCK PURSUANT TO SECTION 151(g) OF THE Delaware GENERAL CORPORATION LAW The undersigned, Michael Cain does hereby certify that: 1. He is the President of Inspyr Therapeutics, Inc., a Delaware corporation (the “Corporation”). 2. The Corporation is authori |
|
| May 14, 2020 |
Form of Series E Preferred Stock Certificate EX-4.36 3 f10k2019ex4-36inspyr.htm FORM OF SERIES E PREFERRED STOCK CERTIFICATE Exhibit 4.36 SE-001 Series E 0% Convertible Preferred [*] Shares Inspyr Therapeutics, Inc. A Delaware Corporation THIS CERTIFIES THAT [*] is the record holder of ([*]) shares of the Series E 0% Convertible Preferred Stock of Inspyr Therapeutics, Inc. transferable only on the register of said company, in person or by du |
|
| May 14, 2020 |
Consent of Liggett & Webb, P.A. Exhibit 23.01 CONSENT OF INDEPENDENT REGISTERED CERTIFICATED PUBLIC ACCOUNTANTS We hereby consent to the incorporation by reference in the Registration Statement on Form S-8 (SEC File No. 333-192553) of Inspyr Therapeutics, Inc. of our report which includes an explanatory paragraph expressing substantial doubt regarding the Company’s ability to continue as a going concern dated May 14, 2020, relat |
|
| May 13, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 13, 2020 Inspyr Therapeutics, Inc. (Exact name of registrant as specified in Charter) Delaware 0001421204 20-0438951 (State or other jurisdiction of incorporation or organization) |
|
| March 30, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 30, 2020 Inspyr Therapeutics, Inc. (Exact name of registrant as specified in Charter) Delaware 0001421204 20-0438951 (State or other jurisdiction of incorporation or organizatio |
|
| March 6, 2020 |
8-K 1 ea119382-8kinspyrtherape.htm CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 6, 2020 Inspyr Therapeutics, Inc. (Exact name of registrant as specified in Charter) Delaware 0001421204 20-0438951 (State or o |
|
| March 6, 2020 |
Form of Debenture for March 2020 Private Placement Exhibit 10.01 NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGI |
|
| December 20, 2019 |
NSPX / Inspyr Therapeutics, Inc. 10-Q - Quarterly Report - QUARTERLY REPORT 10-Q 1 f10q0919inspyrtherapeutics.htm QUARTERLY REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C.20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2019 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Num |
|
| September 30, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 30, 2019 Inspyr Therapeutics, Inc. (Exact name of registrant as specified in Charter) Delaware 000-55331 20-0438951 (State or other jurisdiction of incorporation or organiza |
|
| September 30, 2019 |
Amended and Restated Certificate of Incorporation, effective September 30, 2019 EX-3.01 2 f8k093019ex3-01iinspyrthera.htm EXHIBIT 3.01I Exhibit 3.01(i) AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF INSPYR THERAPEUTICS, INC. a Delaware Corporation The undersigned does hereby certify on behalf of Inspyr Therapeutics, Inc. (the “Corporation”), a corporation organized and existing under the Delaware General Corporation Law, as follows: FIRST: That the undersigned is the du |
|
| September 13, 2019 |
NSPX / Inspyr Therapeutics, Inc. 10-Q - Quarterly Report - QUARTERLY REPORT 10-Q 1 f10q0619inspyrtherapeutics.htm QUARTERLY REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C.20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2019 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: |
|
| September 11, 2019 |
NSPX / Inspyr Therapeutics, Inc. 10-Q - Quarterly Report - QUARTERLY REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2019 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 000-55331 INSPYR THERAPEUTICS, INC. (Exact name of re |
|
| August 6, 2019 |
8-K 1 f8k071519inspyrtherap.htm CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 6, 2019 (July 15, 2019) Inspyr Therapeutics, Inc. (Exact name of registrant as specified in Charter) Delaware 0001421204 20-04389 |
|
| August 6, 2019 |
NSPX / Inspyr Therapeutics, Inc. 10-K - Annual Report - ANNUAL REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 000-55331 INSPYR THERAP |
|
| August 6, 2019 |
Consent of Liggett & Webb, P.A. Exhibit 23.01 CONSENT OF INDEPENDENT REGISTERED CERTIFIED PUBLIC ACCOUNTANTS We hereby consent to the incorporation by reference in the Registration Statement on Form S-8 (SEC File No. 333-192553) of Inspyr Therapeutics, Inc. of our report which includes an explanatory paragraph expressing substantial doubt regarding the Company’s ability to continue as a going concern dated August 6, 2019, relati |
|
| June 14, 2019 |
NSPX / Inspyr Therapeutics, Inc. 10-Q - Quarterly Report - QUARTERLY REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C.20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2018 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 000-55331 INSPYR THERAPEUTICS, INC. (Exact name of |
|
| May 22, 2019 |
NSPX / Inspyr Therapeutics, Inc. 10-Q - Quarterly Report - FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C.20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2018 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 000-55331 INSPYR THERAPEUTICS, INC. (Exact name of reg |
|
| May 22, 2019 |
NSPX / Inspyr Therapeutics, Inc. 10-Q - Quarterly Report - FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C.20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2018 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 000-55331 INSPYR THERAPEUTICS, INC. (Exact name of regi |
|
| April 26, 2019 |
Nominating and Governance Committee Charter Exhibit 99.03 INSPYR THERAPEUTICS NOMINATING AND CORPORATE GOVERNANCE COMMITTEE CHARTER Purpose The purpose of the Nominating and Corporate Governance Committee (the “Committee”) is to: ● Assist the Board by identifying individuals qualified to become Board members, consistent with criteria approved by the Board ● Recommend for the Board’s approval the slate of nominees to be proposed by the Board |
|
| April 26, 2019 |
Leadership Development and Compensation Committee Charter Exhibit 99.02 INSPYR THERAPEUTICS LEADERSHIP DEVELOPMENT AND COMPENSATION COMMITTEE CHARTER Purpose The basic purpose of the Leadership Development and Compensation Committee is to oversee Inspyr Therapeutics’s executive officer compensation programs. The Committee will provide this oversight through a process that supports Inspyr Therapeutics’s business objectives and incorporates sound corporate |
|
| April 26, 2019 |
Exhibit 99.01 INSPYR THERAPEUTICS AUDIT COMMITTEE CHARTER Purpose The purpose of the Audit Committee is to: ● oversee Inspyr Therapeutics’s accounting and financial reporting processes, Inspyr Therapeutics’s internal systems of control and audits of Inspyr Therapeutics’s financial statements. ● oversee Inspyr Therapeutics’s relationship with its independent auditors, including appointing or changi |
|
| April 26, 2019 |
Consent of Liggett & Webb, P.A. Exhibit 23.01 CONSENT OF INDEPENDENT REGISTERED CERTIFIED PUBLIC ACCOUNTANTS We hereby consent to the incorporation by reference in on Registration Statement on Form S-8 (SEC File No. 333-192553) of Inspyr Therapeutics, Inc. of our report which includes an explanatory paragraph expressing substantial doubt regarding the Company’s ability to continue as a going concern dated April 26, 2019, relatin |
|
| April 26, 2019 |
Exhibit 14.01 Code of Ethics and Conduct Last Revised: August 1, 2016 This Code of Ethics and Conduct (the “Code”) applies to all directors, officers, and employees of Inspyr Therapeutics, Inc. (the “Company”) and is designed to deter wrongdoing and promote the following: ● Honest and ethical conduct; ● Full, fair, accurate, timely, and understandable disclosure in reports and documents that are f |
|
| April 26, 2019 |
List of Subsidiaries of Registrant Exhibit 21.01 List of Subsidiaries of Inspyr Therapeutics, Inc. ● Lewis and Clark Pharmaceuticals, Inc. |
|
| April 26, 2019 |
Form of Securities Purchase Agreement for January 2019 Preferred Stock Offering UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2017 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 000-55331 INSPYR THERAP |
|
| April 26, 2019 |
Form of Series D Preferred Stock Certificate EX-4.45 3 s117409ex4-45.htm EXHIBIT 4.45 Exhibit 4.45 SD-001 Series D 0% Convertible Preferred [*] Shares Inspyr Therapeutics, Inc. A Delaware Corporation THIS CERTIFIES THAT [*] is the record holder of ([*]) shares of the Series D 0% Convertible Preferred Stock of Inspyr Therapeutics, Inc. transferable only on the register of said company, in person or by duly authorized attorney, upon surrender |
|
| April 26, 2019 |
EX-3.08(I) 2 s117409ex3-08i.htm EXHIBIT 3.08(I) Exhibit 3.08(i) INSPYR THERAPEUTICS, inc. CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES D 0% CONVERTIBLE PREFERRED STOCK PURSUANT TO SECTION 151(g) OF THE Delaware GENERAL CORPORATION LAW The undersigned, Christopher Lowe does hereby certify that: 1. He is the President of Inspyr Therapeutics, Inc., a Delaware corporatio |
|
| April 26, 2019 |
Form of Securities Purchase Agreement for January 2019 Preferred Stock Offering EX-10.23 4 s117409ex10-23.htm EXHIBIT 10.23 Exhibit 10.23 December [*], 2018 Inspyr Therapeutics, Inc. 31200 Via Colinas #200 Westlake Village, CA 91362 Re: Inspyr Therapeutics, Inc. - Subscription for Shares of Series D Preferred Stock Ladies and Gentlemen: The undersigned hereby acknowledges and agrees to the following: 1. The undersigned hereby subscribes for shares totaling an aggregate consid |
|
| April 2, 2019 |
NSPX / Inspyr Therapeutics, Inc. NT 10-K NT 10-K 1 s117225nt10k.htm NT 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 SEC File Number 000-55331 NOTIFICATION OF LATE FILING (Check One): ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended: December 31, 2018 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on For |
|
| January 22, 2019 |
NSPX / Inspyr Therapeutics, Inc. DEF 14C DEF 14C 1 s115457def14c.htm DEF 14C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: ¨ Preliminary Information Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) x Definitive Information Statement |
|
| January 10, 2019 |
NSPX / Inspyr Therapeutics, Inc. PRE 14C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: ☒ Preliminary Information Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) ☐ Definitive Information Statement Inspyr Therapeutics, Inc. (Name of R |
|
| July 3, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 3, 2018 Inspyr Therapeutics, Inc. (Exact name of registrant as specified in Charter) Delaware 0001421204 20-0438951 (State or other jurisdiction of incorporation or organization) |
|
| July 3, 2018 |
Form of Debenture for July 2018 Private Placement Exhibit 10.02 NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGI |
|
| July 3, 2018 |
Form of Securities Purchase Agreement for July 2018 Private Placement Exhibit 10.01 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of July , 2018, between Inspyr Therapeutics, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). WHEREAS, subject to the terms and condition |
|
| February 15, 2018 |
8-K 1 s1090808k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 14, 2018 (February 9, 2018) Inspyr Therapeutics, Inc. (Exact name of registrant as specified in Charter) Delaware 0001421204 20-0438951 (State or othe |
|
| December 21, 2017 |
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Exhibit 99.01 REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM To the Shareholders of Lewis and Clark Pharmaceuticals, Inc. We have audited the accompanying balance sheets of Lewis and Clark Pharmaceuticals, Inc. (the “Company”) as of December 31, 2016 and 2015, and the related statements of operations, deficiency in stockholder’s equity, and cash flows for the years ended December 31, 2016 |
|
| December 21, 2017 |
Inspyr Therapeutics, Inc. NOTES TO PRO FORMA UNAUDITED FINANCIAL STATEMENTS Exhibit 99.03 Inspyr Therapeutics, Inc. NOTES TO PRO FORMA UNAUDITED FINANCIAL STATEMENTS Unaudited Pro Forma Condensed Financial Information. The Pro forma Unaudited Financial Statements have been prepared in order to present condensed consolidated financial position and results of operations of Inspyr Therapeutics, Inc. and Lewis and Clark Pharmaceuticals, Inc. as if the acquisition had occurred |
|
| December 21, 2017 |
Financial Statements and Exhibits 8-K/A 1 s1084318ka.htm 8-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December [*], 2017 (July 31, 2017) Inspyr Therapeutics, Inc. (Exact name of registrant as specified in Charter) Delaware 0001421204 20-0438951 (State or |
|
| December 21, 2017 |
LEWIS AND CLARK PHARMACEUTICALS, INC. CONDENSED BALANCE SHEETS EX-99.02 3 s108431ex99-02.htm EXHIBIT 99.02 Exhibit 99.02 LEWIS AND CLARK PHARMACEUTICALS, INC. CONDENSED BALANCE SHEETS June 30, 2017 December 31, 2016 (Unaudited) Assets Current assets: Cash $ 5,694 $ 320,946 Prepaid expenses 2,693 2,693 Total current assets 8,387 323,639 Property and equipment, net of accumulated depreciation of $15,902 and $13,517, respectively 12,461 14,846 Total assets $ 20, |
|
| November 20, 2017 |
NSPX / Inspyr Therapeutics, Inc. FORM 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C.20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2017 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 000-55331 INSPYR THERAPEUTICS, INC. (Exact name of |
|
| November 14, 2017 |
NSPX / Inspyr Therapeutics, Inc. NT 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 SEC File Number 000-55331 NOTIFICATION OF LATE FILING (Check One): ? Form 10-K ? Form 20-F ? Form 11-K x Form 10-Q ? Form 10-D ? Form N-SAR ? Form N-CSR For Period Ended: September 30, 2017 ? Transition Report on Form 10-K ? Transition Report on Form 20-F ? Transition Report on Form 11-K ? Transition Report on Form |
|
| November 3, 2017 |
2017 Equity Compensation Plan adopted 11/1/17 Exhibit 4.01 INSPYR THERAPEUTICS, INC. 2017 EQUITY COMPENSATION PLAN Adopted on November 1, 2017 1. Purposes of the Plan. The purposes of this Plan are: ? to attract and retain the best available personnel for positions of substantial responsibility, ? to provide additional incentive to Employees, Directors and Consultants, and ? to promote the success of the Company?s business. The Plan permits t |
|
| November 3, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 3, 2017 (November 1, 2017) Inspyr Therapeutics, Inc. (Exact name of registrant as specified in Charter) Delaware 000-55331 20-0438951 (State or other jurisdiction of incorpor |
|
| September 15, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 15, 2017 (September 12, 2017) Inspyr Therapeutics, Inc. (Exact name of registrant as specified in Charter) Delaware 0001421204 20-0438951 (State or other jurisdiction of inc |
|
| September 12, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 12, 2017 Inspyr Therapeutics, Inc. (Exact name of registrant as specified in Charter) Delaware 0001421204 20-0438951 (State or other jurisdiction of incorporation or organiz |
|
| September 12, 2017 |
Form of Securities Purchase Agreement for September 2017 Private Placement EX-10.01 2 s107467ex10-01.htm EXHIBIT 10.1 Exhibit 10.01 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of September 12, 2017, between Inspyr Therapeutics, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchas |
|
| September 12, 2017 |
Form of Senior Convertible Debenture due 9/12/17 issued pursuant to Securities Purchase Agreement EX-10.02 3 s107467ex10-02.htm EXHIBIT 10.02 Exhibit 10.02 EXHIBIT A NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT B |
|
| September 12, 2017 |
Inspyr Therapeutics Announces Private Placement of Senior Convertible Debentures EX-99.01 5 s107467ex99-01.htm EXHIBIT 99.01 Exhibit 99.01 Inspyr Therapeutics Announces Private Placement of Senior Convertible Debentures WESTLAKE VILLAGE, Calif., September 12, 2017— Inspyr Therapeutics (OTCQB: NSPX), a clinical-stage biotechnology company developing a novel prodrug therapeutic for the treatment of cancer, announced today that the company has entered into definitive agreements w |
|
| September 12, 2017 |
Form of Registration Rights Agreement entered into 9/12/17 EX-10.03 4 s107467ex10-03.htm EXHIBIT 10.03 Exhibit 10.03 EXHIBIT B REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made and entered into as of September 12, 2017, between Inspyr Therapeutics, Inc., a Delaware corporation (the “Company”), and each of the several purchasers signatory hereto (each such purchaser, a “Purchaser” and, collectively, the “Purchasers |
|
| September 12, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 12, 2017 Inspyr Therapeutics, Inc. (Exact name of registrant as specified in Charter) Delaware 0001421204 20-0438951 (State or other jurisdiction of incorporation or organiz |
|
| September 12, 2017 |
Form of Exchange Agreement for September 2017 Private Placement EX-10.01 2 s107465ex10-01.htm EXHIBIT 10.01 Exhibit 10.01 EXCHANGE AGREEMENT EXCHANGE AGREEMENT (the “Agreement”) is made as of the 12th day of September 2017, by and between Inspyr Therapeutics, Inc., a Delaware corporation (the “Company”), and the holders which are signatories on the signature page hereto (the “Holder(s)”). WHEREAS, pursuant to that certain Securities Purchase Agreement, by and |
|
| September 12, 2017 |
Form of Senior Convertible Debenture due 9/12/18 issued pursuant to Exchange Agreement Exhibit 10.02 EXHIBIT A NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFE |
|
| August 14, 2017 |
NSPX / Inspyr Therapeutics, Inc. 10-Q (Quarterly Report) 10-Q 1 s10709310q.htm 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C.20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2017 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 000-55331 INSPYR THERAPEUTIC |
|
| August 3, 2017 |
Form of Share Escrow Agreement pursuant to Lewis & Clark Share Exchange Transaction Exhibit 10.2 SHARE ESCROW AGREEMENT This SHARE ESCROW AGREEMENT (this ?Agreement?) dated as of this day of July 2017 by and among INSPYR THERAPEUTICS, INC., a Delaware corporation (the ?Company?), having an address at 31200 Via Colinas #200, Westlake Village, CA 91362, ROBERT D. THOMPSON, LARRY E. RODMAN, JOHN MONTGOMERY AND GRETCHEN MONTGOMERY, each individuals (the ?Principals?), each having add |
|
| August 3, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 3, 2017 (July 31, 2017) Inspyr Therapeutics, Inc. (Exact name of registrant as specified in Charter) Delaware 0001421204 20-0438951 (State or other jurisdiction of incorporatio |
|
| August 3, 2017 |
Form of Share Exchange Agreement between Inspyr Therapeutics and Lewis & Clark Pharmaceuticals Exhibit 10.1 Share Exchange Agreement This Share Exchange Agreement, dated as of July [*], 2017, is made by and among INSPYR THERAPEUTICS, INC., a Delaware corporation (the ?Acquiror Company?), LEWIS AND CLARK PHARMACEUTICALS, INC., a Virginia corporation (the ?Company?), each of the Persons listed on Schedule I hereto that comprise all of the shareholders of the Company, and each of which is a si |
|
| May 15, 2017 |
Inspyr Therapeutics 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C.20549 FORM 10-Q (Mark one) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2017 Or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 000-55331 INSPYR THERAPEUTICS, INC. (Exact name of reg |
|
| April 24, 2017 |
8-K 1 s1059478k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 24, 2017 (April 18, 2017) Inspyr Therapeutics, Inc. (Exact name of registrant as specified in Charter) Delaware 0001421204 20-0438951 (State or other jur |
|
| April 17, 2017 |
Inspyr Therapeutics 10-K (Annual Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2016 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 000-55331 INSPYR THERAP |
|
| April 17, 2017 |
CONSENT OF INDEPENDENT REGISTERED CERTIFIED PUBLIC ACCOUNTANTS Exhibit 23.01 CONSENT OF INDEPENDENT REGISTERED CERTIFIED PUBLIC ACCOUNTANTS We hereby consent to the incorporation by reference in on Registration Statement on Form S-8 (SEC File No. 333-192553) of Inspyr Therapeutics, Inc. of our report which includes an explanatory paragraph expressing substantial doubt regarding the Company’s ability to continue as a going concern dated April 17, 2017, relatin |
|
| March 31, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 SEC File Number 000-55331 NOTIFICATION OF LATE FILING (Check One): x Form 10-K ? Form 20-F ? Form 11-K ? Form 10-Q ? Form 10-D ? Form N-SAR ? Form N-CSR For Period Ended: December 31, 2016 ? Transition Report on Form 10-K ? Transition Report on Form 20-F ? Transition Report on Form 11-K ? Transition Report on Form |
|
| March 23, 2017 |
424B3 1 v462529424b3.htm 424B3 SUPPLEMENT No. 1 DATED March 23, 2017 (To Prospectus dated February 1, 2017) Rule 424(b)(3) Registration No. 333-215561 6,800,014 Shares Common Stock This prospectus supplement (“Supplement”) modifies, supersedes and supplements information contained in, and should be read in conjunction with, that certain prospectus, dated February 1, 2017 (“Prospectus”), of Inspyr |
|
| March 20, 2017 |
EX-3.01 2 v462102ex3-01.htm EXHIBIT 3.01 Exhibit 3.01 Inspyr Therapeutics, Inc. CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES C CONVERTIBLE PREFERRED STOCK PURSUANT TO SECTION 151 OF THE Delaware GENERAL CORPORATION LAW The undersigned, Christopher Lowe does hereby certify that: 1. He is the President and Secretary of Inspyr Therapeutics, Inc., a Delaware corporation |
|
| March 20, 2017 |
Form of Securities Purchase Agreement for March 2017 – April 2017 Private Placement Exhibit 10.01 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this ?Agreement?) is dated as of March 14, 2017, between Inspyr Therapeutics, Inc., a Delaware corporation (the ?Company?), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a ?Purchaser? and collectively, the ?Purchasers?). WHEREAS, subject to the terms and condit |
|
| March 20, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 20, 2017 (March 14, 2017) Inspyr Therapeutics, Inc. (Exact name of registrant as specified in Charter) Delaware 0001421204 20-0438951 (State or other jurisdiction of (Commission |
|
| March 20, 2017 |
Form of Series C Preferred Stock Certificate Exhibit 4.01 SC-[*] Series C 0% Convertible Preferred [*] Shares Inspyr Therapeutics, Inc. A Delaware Corporation THIS CERTIFIES THAT [Name] is the record holder of [*] ([*]) shares of the Series C 0% Convertible Preferred Stock of Inspyr Therapeutics, Inc. transferable only on the register of said company, in person or by duly authorized attorney, upon surrender of this certificate properly endor |
|
| March 20, 2017 |
Form of Series M, N and O warrants for March 2017 – April 2017 Private Placement Exhibit 10.02 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIS |
|
| March 3, 2017 |
8-K 1 v4611108-k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 3, 2017 (February 28, 2017) Inspyr Therapeutics, Inc. (Exact name of registrant as specified in Charter) Delaware 000-55331 20-0438951 (State or ot |
|
| March 3, 2017 |
Form of Separation Agreement with Russell Richerson dated February 28, 2017 Exhibit 10.01 SEPARATION AGREEMENT This Separation Agreement ("Agreement") is made by and between Inspyr Therapeutics, Inc. (the "Company"), and Russell Richerson ("Employee"). WHEREAS, on September 2, 2009 the Company and Employee entered into an employment agreement (which together with all prior amendment thereto shall be the ?Employment Agreement); WHEREAS, on September 2, 2009 the Company and |
|
| February 1, 2017 |
424B3 1 v458073424b3.htm FORM 424(B)(3) SUPPLEMENT No. 2 DATED February 1, 2017 (To Prospectus dated August 3, 2016) Rule 424(b)(3) Registration No. 333-208918 10,072,736 shares of Common Stock issuable upon the exercise of outstanding warrants And 28,958,440 shares of Common Stock being sold by Selling Shareholders This prospectus supplement (“Supplement”) modifies, supersedes and supplements inf |
|
| February 1, 2017 |
424B3 1 v457846424b3.htm 424B3 PROSPECTUS Rule 424(b)(3) Registration No. 333-215561 6,800,014 Shares Common Stock This prospectus relates to the resale of 6,800,014 shares of our common stock, by the selling stockholders identified in the selling stockholders tables beginning on page 16 of this prospectus (“Selling Stockholders”). We will not receive any proceeds from the sale of these shares by |
|
| January 30, 2017 |
CORRESP 1 filename1.htm INSPYR THERAPEUTICS, INC. January 30, 2017 Suzanne Hayes Assistant Director Office of Healthcare and Insurance Division of Corporation Finance United States Securities and Exchange Commission Washington, DC 20549 RE: Inspyr Therapeutics, Inc. Registration Statement on Form S-1 Filed January 13, 2017 File No. 333-215561 Dear Ms. Hayes: We have been advised by your staff tele |
|
| January 27, 2017 |
CORRESP 1 filename1.htm INSPYR THERAPEUTICS, INC. January 27, 2017 Suzanne Hayes Assistant Director Office of Healthcare and Insurance Division of Corporation Finance United States Securities and Exchange Commission Washington, DC 20549 RE: Inspyr Therapeutics, Inc. Registration Statement on Form S-1 Filed January 13, 2017 File No. 333-215561 Dear Ms. Hayes: We are submitting this letter in respon |
|
| January 13, 2017 |
Exhibit 4.41 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST |
|
| January 13, 2017 |
As filed with the Securities and Exchange Commission on January 13, 2017 Registration No. |
|
| January 13, 2017 |
Exhibit 5.01 SILVESTRE LAW GROUP, P.C. 31200 Via Colinas, Suite 200 Westlake Village, CA 91362 (818) 597-7552 Fax (805) 553-9783 January 13, 2017 Inspyr Therapeutics, Inc. 31200 Via Colinas, Suite 200 Westlake Village, CA 91362 Ladies and Gentlemen: We have acted as counsel to Inspyr Therapeutics, Inc., a Delaware corporation (the ? Company ?) in connection with the Registration Statement on Form |
|
| January 13, 2017 |
CONSENT OF INDEPENDENT REGISTERED CERTIFIED PUBLIC ACCOUNTANTS Exhibit 23.01 CONSENT OF INDEPENDENT REGISTERED CERTIFIED PUBLIC ACCOUNTANTS We hereby consent to the use in this Form S-1 Registration Statement of our report dated March 30, 2016 (January 13, 2017 as to the effects of the reverse stock-split described in Note 14), relating to the financial statements of Inspyr Therapeutics, Inc. (fka GenSpera, Inc.), which appear in this Registration Statement a |
|
| December 12, 2016 |
Form of Registration Rights Agreement for December 2016 Private Placement Exhibit 10.02 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this ?Agreement?) is made and entered into as of December 9, 2016, between Inspyr Therapeutics, Inc., a Delaware corporation (the ?Company?), and each of the several purchasers signatory hereto (each such purchaser, a ?Purchaser? and, collectively, the ?Purchasers?). This Agreement is made pursuant to the Securities Pu |
|
| December 12, 2016 |
Inspyr Announces Private Placement of $1.0 Million EX-99.01 7 v454787ex99-01.htm EXHIBIT 99.01 Exhibit 99.01 Inspyr Announces Private Placement of $1.0 Million WESTLAKE VILLAGE, CA, December 12, 2016 Inspyr Therapeutics (OTCQB:NSPX) (“Inspyr” or the “Company”), a biotech company developing novel prodrug therapeutics for the treatment of cancer, today announced that it has entered into definitive securities purchase agreements with institutional an |
|
| December 12, 2016 |
Form of Series B Preferred Stock Certificate Exhibit 4.01 SB-[*] Series B 0% Convertible Preferred [*] Shares Inspyr Therapeutics, Inc. A Delaware Corporation THIS CERTIFIES THAT [Name] is the record holder of [*] ([*]) shares of the Series B 0% Convertible Preferred Stock of Inspyr Therapeutics, Inc. transferable only on the register of said company, in person or by duly authorized attorney, upon surrender of this certificate properly endor |
|
| December 12, 2016 |
8-K 1 v4547878k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 12, 2016 (December 9, 2016) Inspyr Therapeutics, Inc. (Exact name of registrant as specified in Charter) Delaware 0001421204 20-0438951 (State or |
|
| December 12, 2016 |
Form of Series J, K and L Warrants for December 2016 Private Placement EX-10.03 6 v454787ex10-03.htm EXHIBIT 10.3 Exhibit 10.03 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR |
|
| December 12, 2016 |
EX-3.01 2 v454787ex3-01.htm EXHIBIT 3.01 Exhibit 3.01 EXHIBIT A Inspyr Therapeutics, Inc. CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES B CONVERTIBLE PREFERRED STOCK PURSUANT TO SECTION 151 OF THE Delaware GENERAL CORPORATION LAW The undersigned, Christopher Lowe does hereby certify that: 1. He is the President and Secretary of Inspyr Therapeutics, Inc., a Delaware co |
|
| December 12, 2016 |
Form of Securities Purchase Agreement for December 2016 Private Placement EX-10.01 4 v454787ex10-01.htm EXHIBIT 10.01 Exhibit 10.01 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of December 9, 2016, between Inspyr Therapeutics, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchase |
|
| November 18, 2016 |
Inspyr Therapeutics 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2016 Or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 000-55331 INSPYR THERAPEUTICS, INC. (Exact name o |
|
| November 14, 2016 |
NT 10-Q 1 v452902nt10q.htm NT 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 SEC FILE NUMBER 000-55331 NOTIFICATION OF LATE FILING CUSIPNUMBER 45782A 205 (Check one): ¨ Form 10-K ¨ Form 20-F ¨ Form 11-K x Form 10-Q ¨ Form 10-D ¨ Form N-SAR ¨ Form N-CSR For Period Ended: September 30, 2016 ¨ Transition Report on Form 10-K ¨ Transition Report on Form 20-F ¨ |
|
| November 10, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 10, 2016 (November 4, 2016) Inspyr Therapeutics, Inc. (Exact name of registrant as specified in Charter) Delaware 000-55331 20-0438951 (State or other jurisdiction of incorpo |
|
| November 10, 2016 |
Amended and Restated Certificate of Incorporation dated October 21, 2016 Exhibit 3.01(i) AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF INSPYR THERAPEUTICS, INC. a Delaware Corporation The undersigned does hereby certify on behalf of Inspyr Therapeutics, Inc. (the ?Corporation?), a corporation organized and existing under the Delaware General Corporation Law, as follows: FIRST: That the undersigned is the duly elected and acting Chief Executive Officer of the Cor |
|
| October 20, 2016 |
Regulation FD Disclosure, Financial Statements and Exhibits 8-K 1 v4508698k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 20, 2016 Inspyr Therapeutics, Inc. (Exact name of registrant as specified in Charter) Delaware 0001421204 20-0438951 (State or other jurisdiction |
|
| October 20, 2016 |
Exhibit 99.01 Inspyr Broadens Intellectual Property Portfolio with New Patent Issued on Methods for Producing Cancer Compounds WESTLAKE VILLAGE, CA (October 20, 2016) ? Inspyr Therapeutics, Inc. (OTCQB:NSPX), a biotech company developing a novel prodrug therapeutic for the treatment of cancer, announced that the United States Patent and Trademark Office (USPTO) recently issued patent 9,446,141 B2 |
|
| October 14, 2016 |
Inspyr Therapeutics Appoints Claire Thom, Pharm.D. to Board of Directors Exhibit 99.01 Inspyr Therapeutics Appoints Claire Thom, Pharm.D. to Board of Directors WESTLAKE VILLAGE, CA (October 12, 2016) ? Inspyr Therapeutics, Inc. (OTCQB:NSPX), a biotech company developing a novel prodrug therapeutic for the treatment of cancer, announced today the appointment of Claire Thom, Pharm.D. to its Board of Directors. ?Claire has broad experience in the global oncology industry, |
|
| October 14, 2016 |
Inspyr Therapeutics Appoints Richard Buller, M.D., Ph.D. to Board of Directors Exhibit 99.02 Inspyr Therapeutics Appoints Richard Buller, M.D., Ph.D. to Board of Directors WESTLAKE VILLAGE, CA (October 13, 2016) ? Inspyr Therapeutics, Inc. (OTCQB:NSPX), a biotech company developing a novel prodrug therapeutic for the treatment of cancer, announced today the appointment of Richard Buller, M.D., Ph.D. to its Board of Directors. ?We are excited to have Rich join the Board as hi |
|
| October 14, 2016 |
8-K 1 v4505298k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 14, 2016 (October 12, 2016) Inspyr Therapeutics, Inc. (Exact name of registrant as specified in Charter) Delaware 0001421204 20-0438951 (State or |
|
| October 11, 2016 |
SUPPLEMENT No. 1 DATED October 11, 2016 (To Prospectus dated August 3, 2016) Rule 424(b)(3) Registration No. 333-208918 10,072,736 shares of Common Stock issuable upon the exercise of outstanding warrants And 28,958,440 shares of Common Stock being sold by Selling Shareholders This prospectus supplement (?Supplement?) modifies, supersedes and supplements information contained in, and should be rea |
|
| September 12, 2016 |
Form of Indemnification Agreement with Directors and Officers Exhibit 10.01 INDEMNIFICATION AGREEMENT This Indemnification Agreement ("Agreement") is entered into as of the [*] day of [*], 20[*] by and between Inspyr Therapeutics, Inc. a Delaware corporation (the ?Company?), and [*] ("Indemnitee"). RECITALS A. The Company and Indemnitee recognize the continued difficulty in obtaining liability insurance for the Company's directors and officers, the significa |
|
| September 12, 2016 |
Termination of a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 12, 2016 (September 9, 2016) Inspyr Therapeutics, Inc. (Exact name of registrant as specified in Charter) Delaware 0001421204 20-0438951 (State or other jurisdiction of inco |
|
| August 18, 2016 |
Exhibit 24 LIMITED POWER OF ATTORNEY The undersigned does hereby make, constitute and appoint Silvestre Law Group, P. |
|
| August 17, 2016 |
Exhibit 24 LIMITED POWER OF ATTORNEY The undersigned does hereby make, constitute and appoint Silvestre Law Group, P. |
|
| August 15, 2016 |
NSPX / Inspyr Therapeutics, Inc. 10-Q - Quarterly Report - FORM 10-Q 10-Q 1 v44589410q.htm FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C.20549 FORM 10-Q (Mark one) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2016 Or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 000-55331 Inspyr Therap |
|
| August 15, 2016 |
NSPX / Inspyr Therapeutics, Inc. 10-Q - Quarterly Report - FORM 10-Q 10-Q 1 v44589410q.htm FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C.20549 FORM 10-Q (Mark one) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2016 Or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 000-55331 Inspyr Therap |
|
| August 10, 2016 |
Inspyr Therapeutics Appoints Ronald Shazer, M.D., as Senior Vice President and Chief Medical Officer EX-99.1 4 v446564ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Inspyr Therapeutics Appoints Ronald Shazer, M.D., as Senior Vice President and Chief Medical Officer SAN ANTONIO (August 8, 2016) – Inspyr Therapeutics, Inc. (OTCQB: NSPX), a clinical-stage biotechnology company developing novel prodrug therapeutics for the treatment of cancer, announces the appointment of Ronald Shazer, M.D. as Senior Vice Pre |
|
| August 10, 2016 |
Form of Proprietary Information, Inventions and Competition Agreement Exhibit 10.2 INSPYR THERAPEUTICS, INC. (FKA GENSPERA, INC.) CONFIDENTIAL INFORMATION AND INVENTION ASSIGNMENT AGREEMENT Employee Name: Ronald Shazer, MD Effective Date: August 8, 2016 As a condition of my becoming employed (or my employment being continued) by Inspyr Therapeutics, Inc. (fka GenSpera, Inc.), a Delaware corporation, or any of its current or future subsidiaries, affiliates, successor |
|
| August 10, 2016 |
8-K 1 v4465648k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 10, 2016 (August 8, 2016) Inspyr Therapeutics, Inc. (Exact name of registrant as specified in Charter) Delaware 0001421204 20-0438951 (State or oth |
|
| August 10, 2016 |
Form of Proprietary Information, Inventions and Competition Agreement Exhibit 10.1 EMPLOYMENT AGREEMENT This Employment Agreement (this ?Agreement?) is made and entered into as of this 8th day of August 2016, by and between Inspyr Therapeutics, Inc. (fka GenSpera, Inc.), a Delaware corporation (the ?Company?), and Ronald L. Shazer, M.D. (the ?Employee?). WITNESSETH: WHEREAS, the Company desires to employ Employee as its Senior Vice President and Chief Medical Office |
|
| August 10, 2016 |
Form of Proprietary Information, Inventions and Competition Agreement Exhibit 10.1 EMPLOYMENT AGREEMENT This Employment Agreement (this ?Agreement?) is made and entered into as of this 8th day of August 2016, by and between Inspyr Therapeutics, Inc. (fka GenSpera, Inc.), a Delaware corporation (the ?Company?), and Ronald L. Shazer, M.D. (the ?Employee?). WITNESSETH: WHEREAS, the Company desires to employ Employee as its Senior Vice President and Chief Medical Office |
|
| August 10, 2016 |
8-K 1 v4465648k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 10, 2016 (August 8, 2016) Inspyr Therapeutics, Inc. (Exact name of registrant as specified in Charter) Delaware 0001421204 20-0438951 (State or oth |
|
| August 10, 2016 |
Form of Proprietary Information, Inventions and Competition Agreement Exhibit 10.2 INSPYR THERAPEUTICS, INC. (FKA GENSPERA, INC.) CONFIDENTIAL INFORMATION AND INVENTION ASSIGNMENT AGREEMENT Employee Name: Ronald Shazer, MD Effective Date: August 8, 2016 As a condition of my becoming employed (or my employment being continued) by Inspyr Therapeutics, Inc. (fka GenSpera, Inc.), a Delaware corporation, or any of its current or future subsidiaries, affiliates, successor |
|
| August 10, 2016 |
Inspyr Therapeutics Appoints Ronald Shazer, M.D., as Senior Vice President and Chief Medical Officer EX-99.1 4 v446564ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Inspyr Therapeutics Appoints Ronald Shazer, M.D., as Senior Vice President and Chief Medical Officer SAN ANTONIO (August 8, 2016) – Inspyr Therapeutics, Inc. (OTCQB: NSPX), a clinical-stage biotechnology company developing novel prodrug therapeutics for the treatment of cancer, announces the appointment of Ronald Shazer, M.D. as Senior Vice Pre |
|
| August 5, 2016 |
Christopher Lowe employment Agreement Exhibit 10.01 EMPLOYMENT AGREEMENT This Employment Agreement (this ?Agreement?) is made and entered into as of this 2nd day of August 2016, by and between GenSpera, Inc., a Delaware corporation (the ?Company?), and Christopher Lowe (the ?Employee?). WITNESSETH : WHEREAS, the Company desires to employ Employee as its Chief Executive Officer and Employee desires to accept such employment; and WHEREA |
|
| August 5, 2016 |
Exhibit 10.02 INSPYR THERAPEUTICS, INC. (FKA GENSPERA, INC.) CONFIDENTIAL INFORMATION AND INVENTION ASSIGNMENT AGREEMENT Employee Name: Christopher Lowe Effective Date: August 2, 2016 As a condition of my becoming employed (or my employment being continued) by Inspyr Therapeutics, Inc. (fka GenSpera, Inc.), a Delaware corporation, or any of its current or future subsidiaries, affiliates, successor |
|
| August 5, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 5, 2016 (August 2, 2016) Inspyr Therapeutics, Inc. (Exact name of registrant as specified in Charter) Delaware 0001421204 20-0438951 (State or other jurisdiction of incorporati |
|
| August 5, 2016 |
Inspyr Therapeutics Appoints Christopher Lowe Chief Executive Officer and Director Exhibit 99.01 Inspyr Therapeutics Appoints Christopher Lowe Chief Executive Officer and Director SAN ANTONIO (August 4, 2016) ? Inspyr Therapeutics, Inc. (OTCQB: NSPX), a clinical-stage biotechnology company developing novel prodrug therapeutics for the treatment of cancer, announces that Christopher Lowe has been appointed President and Chief Executive Officer, and as a member of the Company?s Bo |
|
| August 3, 2016 |
424B3 1 v445951424b3.htm 424B3 PROSPECTUS Rule 424(b)(3) Registration No. 333-208918 10,072,736 shares of Common Stock issuable upon the exercise of outstanding warrants And 28,958,440 shares of Common Stock being sold by Selling Shareholders This prospectus covers the sale and issuance of up to 10,072,736 shares of our common stock (“Shares”) to holder of our outstanding warrants (“Investor Warra |
|
| August 2, 2016 |
Amendment to the Amended and Restated Certificate of Incorporation, effective August 1, 2016 Exhibit 3.01 |
|
| August 2, 2016 |
GenSpera Announces Name Change to Inspyr Therapeutics Exhibit 99.01 GenSpera Announces Name Change to Inspyr Therapeutics SAN ANTONIO (August 1, 2016) ? GenSpera, Inc. (OTC/QB: GNSZ), a clinical-stage biotechnology company developing a novel prodrug therapeutic for the treatment of cancer, announces that it will change its corporate name to Inspyr Therapeutics, Inc. and will begin trading on the OTCQB under the ticker symbol NSPX effective August 2, |
|
| August 2, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 2, 2016 (August 1, 2016) Inspyr Therapeutics, Inc (Exact name of registrant as specified in Charter) Delaware 0001421204 20-0438951 (State or other jurisdiction of incorporatio |
|
| July 20, 2016 |
Form of Inducement Award non-Qualified Stock Option Grant Exhibit 4.01 GENSPERA, INC. INDUCEMENT AWARD STOCK OPTION PLAN SECTION 1. GENERAL PURPOSE OF THE PLAN; DEFINITIONS The name of the plan is the GenSpera, Inc. Inducement Award Stock Option Plan (the ?Plan?). The purpose of the Plan is to provide non-qualified stock options to individuals who were not previously employees or non-employee directors of GenSpera, Inc. (the ?Company?) (or following such |
|
| July 20, 2016 |
Form of Inducement Award non-Qualified Stock Option Grant Exhibit 4.02 GENSPERA. INC. NON-QUALIFIED STOCK OPTION AGREEMENT Name of Optionee: [*] No. of Option Shares: [*] Option Exercise Price per Share: [*] Grant Date: [*] Expiration Date: [*] GenSpera, Inc., (the “Company”) hereby grants to the Optionee named above a non-qualified option (the “Stock Option”) to purchase on or prior to the Expiration Date specified above, subject to the restrictions con |
|
| July 20, 2016 |
8-K 1 v4445238k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 20, 2016 (July 15, 2016) GENSPERA, INC. (Exact name of registrant as specified in Charter) Delaware 0001421204 20-0438951 (State or other jurisdiction of |
|
| July 19, 2016 |
Exhibit 5.01 SILVESTRE LAW GROUP, P.C. 31200 Via Colinas, Suite 200 Westlake Village, CA 91362 (818) 597-7552 Fax (805) 553-9783 July 19, 2016 GenSpera, Inc. 2511 N. Loop 1604 W, Suite 204 San Antonio, TX 78258 Ladies and Gentlemen: We have acted as counsel to GenSpera, Inc., a Delaware corporation (the ?Company?) in connection with the Post-Effective Amendment No. 1 to the Registration Statement |
|
| July 19, 2016 |
CONSENT OF INDEPENDENT REGISTERED CERTIFIED PUBLIC ACCOUNTANTS EXHIBIT 23.01 CONSENT OF INDEPENDENT REGISTERED CERTIFIED PUBLIC ACCOUNTANTS We hereby consent to the use in this Post-Effective Amendment No. 1 to the Form S-1 Registration Statement of our report dated March 30, 2016, relating to the financial statements of GenSpera, Inc., which appear in this Registration Statement and related Prospectus. Our report includes an explanatory paragraph expressing |
|
| July 19, 2016 |
As filed with the Securities and Exchange Commission on July 19, 2016 Registration No. |
|
| May 13, 2016 |
GenSpera FORM 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C.20549 FORM 10-Q (Mark one) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2016 Or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 000-55331 GENSPERA, INC. (Exact name of registrant as |
|
| May 12, 2016 |
Exhibit 7.01 EMPLOYMENT AGREEMENT This Employment Agreement (the “Agreement”), dated as of September 2, 2009 (the “Effective Date”), is made by and between GenSpera, Inc., a Delaware corporation (the “Company”), and Craig Dionne (“Executive”). This Agreement is intended to confirm the understanding and set forth the agreement between the Company and Executive with respect to Executive’s employment |
|
| May 12, 2016 |
NSPX / Inspyr Therapeutics, Inc. / DIONNE CRAIG A - SC 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934* GenSpera, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 37251Q118 (CUSIP Number) Craig A. Dionne, Ph.D. 14439 NW Military Highway, Suite 108, #202 San Antonio, TX 78231 (210) 204-6194 (Name, Address and Telephone Number of Person Authorized to Receive |
|
| March 30, 2016 |
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Exhibit 23.01 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We hereby consent to the incorporation by reference in the Registration Statement on Form S-8 (SEC File No. 333-192553) of GenSpera, Inc. of our report which includes an explanatory paragraph as to the Company’s ability to continue as a going concern dated March 30, 2016 relating to our audit of the financial statements which a |
|
| March 30, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2015 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to .. Commission File Number 000-55331 GENSPERA, IN |
|
| March 22, 2016 |
GenSpera Announces Management Changes Exhibit 99.01 GenSpera Announces Management Changes SAN ANTONIO (March 22, 2016) ? GenSpera, Inc. (OTC/QB: GNSZ), a biotech company developing a novel prodrug therapeutic for the treatment of cancer, announces that Craig A. Dionne, Ph.D., has resigned as GenSpera?s Chairman of the Board and as a Director, and has submitted a notice of termination as GenSpera?s CEO and CFO, all effective immediatel |
|
| March 22, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 22, 2016 (March 16, 2016) GENSPERA, INC. (Exact name of registrant as specified in Charter) Delaware 000-55331 20-0438951 (State or other jurisdiction of incorporation or organi |
|
| March 11, 2016 |
GenSpera Engages FLG Partners LLC and Partner Chris Lowe for Strategic Business Advisory Services Exhibit 99.01 GenSpera Engages FLG Partners LLC and Partner Chris Lowe for Strategic Business Advisory Services SAN ANTONIO (March 11, 2016) ? GenSpera, Inc. (OTC/QB: GNSZ), a biotech company developing a novel prodrug therapeutic for the treatment of cancer, announces that the Company?s board of directors has engaged FLG Partners, LLC and its partner Chris Lowe to provide strategic advice to furt |
|
| March 11, 2016 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 11, 2016 GENSPERA, INC. (Exact name of registrant as specified in Charter) Delaware 0001421204 20-0438951 (State or other jurisdiction of incorporation or organization) (Commiss |
|
| February 16, 2016 |
NSPX / Inspyr Therapeutics, Inc. / DIONNE CRAIG A - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 (Amendment No. 1)* GenSpera, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 37251Q118 (CUSIP Number) 12/31/2015 (Date of Event Which Requir |
|
| January 29, 2016 |
32,839,529 Shares Common Stock PROSPECTUS Filed Pursuant to Rule 424(b)(3) Registration No. 333-208918 32,839,529 Shares Common Stock This prospectus relates to the resale of 32,839,529 shares of our common stock, by the selling stockholders identified in the selling stockholders tables beginning on page 19 of this prospectus (?Selling Stockholders?). We will not receive any proceeds from the sale of these shares by the Selling |
|
| January 28, 2016 |
GENSPERA, INC. January 28, 2016 Suzanne Hayes Assistant Director Office of Healthcare and Insurance Division of Corporation Finance United States Securities and Exchange Commission Washington, DC 20549 RE: GenSpera, Inc. Amendment No. 1 to Registration Statement on Form S-1 Filed January 22, 2016 File No. 333-208918 Dear Ms. Hayes: We have been advised by your staff telephonically that there are n |
|
| January 22, 2016 |
Exhibit 5.01 SILVESTRE LAW GROUP, P.C. 31200 Via Colinas, Suite 200 Westlake Village, CA 91362 (818) 597-7552 Fax (805) 553-9783 January 22, 2016 GenSpera, Inc. 2511 N. Loop 1604 W, Suite 204 San Antonio, TX 78258 Ladies and Gentlemen: We have acted as counsel to GenSpera, Inc., a Delaware corporation (the ? Company ?) in connection with the Amendment No.1 to the Registration Statement on Form S-1 |
|
| January 22, 2016 |
CONSENT OF INDEPENDENT REGISTERED CERTIFIED PUBLIC ACCOUNTANTS EXHIBIT 23.01 CONSENT OF INDEPENDENT REGISTERED CERTIFIED PUBLIC ACCOUNTANTS We hereby consent to the use in this Amendment No.1 to the Form S-1 Registration Statement of our report dated March 20, 2015, relating to the financial statements of GenSpera, Inc., which appear in this Registration Statement and related Prospectus. Our report includes an explanatory paragraph expressing substantial doub |
|
| January 22, 2016 |
S-1/A 1 v429220s1a.htm S-1/A As filed with the Securities and Exchange Commission on January 22, 2016 Registration No. 333-208918 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 GENSPERA, INC. (Exact name of registrant as specified in its charter) Delaware 2834 20-0438951 (State or jurisdict |
|
| January 22, 2016 |
GENSPERA, INC. January 22, 2016 Suzanne Hayes Assistant Director Office of Healthcare and Insurance Division of Corporation Finance United States Securities and Exchange Commission Washington, DC 20549 RE: GenSpera, Inc. Registration Statement on Form S-1 Filed January 8, 2016 File No. 333-208918 Dear Ms. Hayes: We are submitting this letter in response to your comments of January 19, 2016 with re |
|
| January 11, 2016 |
Exhibit 99.01 1 Investor Presentation January 2016 OTC/QB : GNSZ www.GenSpera.com Craig A. Dionne, PhD President & CEO 2 Forward - Looking Statements Any statements that are not historical facts are forward - looking statements that involve risks and uncertainties that could cause actual results to differ materially from those in the forward - looking statements, which may include, but are not lim |
|
| January 11, 2016 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 11, 2016 GENSPERA, INC. (Exact name of registrant as specified in Charter) Delaware 0001421204 20-0438951 (State or other jurisdiction of incorporation or organization) (Commi |
|
| January 11, 2016 |
Exhibit 99.02 1 Corporate Presentation January 2016 OTC QB : GNSZ www.GenSpera.com Craig A. Dionne, PhD President & CEO 2 Safe Harbor Statement Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995: Any statements that are not historical facts are forward - looking statements that involve risks and uncertainties that could cause actual results to differ materially from t |
|
| January 8, 2016 |
CONSENT OF INDEPENDENT REGISTERED CERTIFIED PUBLIC ACCOUNTANTS EXHIBIT 23.01 CONSENT OF INDEPENDENT REGISTERED CERTIFIED PUBLIC ACCOUNTANTS We hereby consent to the use in this Form S-1 Registration Statement of our report dated March 20, 2015, relating to the financial statements of GenSpera, Inc., which appear in this Registration Statement and related Prospectus. Our report includes an explanatory paragraph expressing substantial doubt regarding the Compan |
|
| January 8, 2016 |
Exhibit 5.01 SILVESTRE LAW GROUP, P.C. 31200 Via Colinas, Suite 200 Westlake Village, CA 91362 (818) 597-7552 Fax (805) 553-9783 January 8, 2016 GenSpera, Inc. 2511 N. Loop 1604 W, Suite 204 San Antonio, TX 78258 Ladies and Gentlemen: We have acted as counsel to GenSpera, Inc., a Delaware corporation (the ? Company ?) in connection with the Registration Statement on Form S-1 (the ? Registration St |
|
| January 8, 2016 |
As filed with the Securities and Exchange Commission on January 8, 2016 S-1 1 v425134s1.htm S-1 As filed with the Securities and Exchange Commission on January 8, 2016 Registration No. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 GENSPERA, INC. (Exact name of registrant as specified in its charter) Delaware 2834 20-0438951 (State or jurisdiction of incorporation or organization |
|
| January 8, 2016 |
Exhibit 3.02 GENSPERA, INC. CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES A 0% CONVERTIBLE PREFERRED STOCK PURSUANT TO SECTION 151(G) OF THE DELAWARE GENERAL CORPORATION LAW The undersigned, Craig Dionne, PhD and Russell Richerson, PhD, do hereby certify that: 1. They are the President and Secretary, respectively, of GenSpera, Inc., a Delaware corporation (the “Corpor |
|
| January 6, 2016 |
Financial Statements and Exhibits, Other Events 8-K 1 v4284438k.htm CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 6, 2016 GENSPERA, INC. (Exact name of registrant as specified in Charter) Delaware 0001421204 20-0438951 (State or other jurisdiction of inc |
|
| January 6, 2016 |
GenSpera Issues Letter to Stockholders EX-99.01 2 v428443ex99-01.htm EXHIBIT 99.01 Exhibit 99.01 GenSpera Issues Letter to Stockholders SAN ANTONIO (January 6, 2016) – GenSpera, Inc. (OTC/QB: GNSZ), a biotech company developing a novel prodrug therapeutic for the treatment of cancer, announces that President and CEO Craig A. Dionne, Ph.D., has issued the following letter to stockholders. To My Fellow Stockholders: During 2015 GenSpera |
|
| December 23, 2015 |
Form of Series H and I Common Stock Purchase Warrants for December 2015 Private Placement EX-10.05 8 v427710ex10-05.htm EXHIBIT 10.05 Exhibit 10.05 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED O |
|
| December 23, 2015 |
Form of Series M, N and O warrants for March 2017 – April 2017 Private Placement Exhibit 10.02 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this ?Agreement?) is made and entered into as of December 23, 2015, between GenSpera, Inc., a Delaware corporation (the ?Company?), and each of the several purchasers signatory hereto (each such purchaser, a ?Purchaser? and, collectively, the ?Purchasers?). This Agreement is made pursuant to the Securities Purchase Agr |
|
| December 23, 2015 |
Form of Series A Preferred Stock Certificate Exhibit 4.01 SA-[*] Series A Convertible Preferred [*] Shares GenSpera, Inc. A Delaware Corporation THIS CERTIFIES THAT [Name] is the record holder of [*] ([*]) shares of the Series A 0% Convertible Preferred Stock of GenSpera, Inc. transferable only on the register of said company, in person or by duly authorized attorney, upon surrender of this certificate properly endorsed or assigned. This cer |
|
| December 23, 2015 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 23, 2015 GENSPERA, INC. (Exact name of registrant as specified in Charter) Delaware 0001421204 20-0438951 (State or other jurisdiction of incorporation or organization) (Commission File No |
|
| December 23, 2015 |
SUPPLEMENT No. 1 DATED DECEMBER 23, 2015 (To Prospectus dated August 19, 2015) Rule 424(b)(3) Registration No. 333-206242 18,555,308 Common Shares This prospectus supplement (“Supplement”) modifies and supplements information contained in, and should be read in conjunction with, that certain prospectus, dated August 19, 2015 (“Prospectus”), of GenSpera, Inc. (”Company). The Prospectus relates to t |
|
| December 23, 2015 |
Form of Series F and Series G Common Stock Purchase Warrants for December 2015 Private Placement Exhibit 10.03 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIS |
|
| December 23, 2015 |
Form of Securities Purchase Agreement for March 2017 – April 2017 Private Placement Exhibit 10.01 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this ?Agreement?) is dated as of December 23, 2015, between GenSpera, Inc., a Delaware corporation (the ?Company?), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a ?Purchaser? and collectively, the ?Purchasers?). WHEREAS, subject to the terms and conditions set |
|
| December 23, 2015 |
GenSpera Announces Private Placement of $2.5 Million Exhibit 99.01 December 23, 2015 GenSpera Announces Private Placement of $2.5 Million SAN ANTONIO, December 23, 2015? GenSpera, Inc. (OTCQB: GNSZ) (?GenSpera? or the ?Company?), a biotech company developing a novel prodrug therapeutic for the treatment of cancer, today announced that it has entered into definitive agreements with institutional investors, led by a healthcare-dedicated fund, for the |
|
| December 23, 2015 |
EX-3.01 2 v427710ex3-01.htm EXHIBIT 3.01 Exhibit 3.01 genspera, inc. CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES A 0% CONVERTIBLE PREFERRED STOCK PURSUANT TO SECTION 151(g) OF THE Delaware GENERAL CORPORATION LAW The undersigned, Craig Dionne, PhD and Russell Richerson, PhD, do hereby certify that: 1. They are the President and Secretary, respectively, of GenSpera, |
|
| December 23, 2015 |
Form of Amendment Agreement from December 2015 Private Placement Exhibit 10.04 WARRANT AMENDMENT AGREEMENT This Warrant Amendment Agreement (this ?Agreement?), dated as of December 23, 2015, is by and between GenSpera, Inc., a Delaware corporation (the ?Company?) and the undersigned holders (the ?Holders?) with respect to (i) those certain Series D Common Stock Purchase Warrants (the ?Series D Warrants?) issued by the Company, which Series D Warrant is exercisa |
|
| December 8, 2015 |
GenSpera to Present at ICV Manhattan Investor Conference Exhibit 99.01 GenSpera to Present at ICV Manhattan Investor Conference SAN ANTONIO, December 8, 2015 ? GenSpera, Inc. (OTC/QB: GNSZ), a biotech company developing a novel prodrug therapeutic for the treatment of cancer, announces that President and CEO Craig A. Dionne, Ph.D., will present a corporate overview at ICV Manhattan Investor Conference today, Tuesday, December 8, 2015, at 10:15 a.m. East |
|
| December 8, 2015 |
Financial Statements and Exhibits, Other Events 8-K 1 v4264658k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 8, 2015 GENSPERA, INC. (Exact name of registrant as specified in Charter) Delaware 0001421204 20-0438951 (State or other jurisdiction of incorpor |
|
| December 8, 2015 |
Exhibit 99.02 1 ICV Conference December 8 - 9, 2015 OTC/QB : GNSZ www.GenSpera.com Craig A. Dionne, PhD President & CEO 2 Forward - Looking Statements Any statements that are not historical facts are forward - looking statements that involve risks and uncertainties that could cause actual results to differ materially from those in the forward - looking statements, which may include, but are not li |
|
| November 23, 2015 |
Exhibit 99.02 ? Two stage, single-arm, open label single-institution phase II clinical trial of G-202 in recurrent or progressive glioblastoma ? Accrual goal of 34 efficacy-evaluable patients, defined as those that receive two cycles of drug followed by disease assessment ? Up to 3 prior recurrences allowed ? Primary endpoint: 6 month PFS ? Secondary endpoints include safety, efficacy, effects of |
|
| November 23, 2015 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 23, 2015 (November 20, 2015) GENSPERA, INC. (Exact name of registrant as specified in Charter) Delaware 0001421204 20-0438951 (State or other jurisdiction of incorporation or |
|
| November 23, 2015 |
Exhibit 99.01 Mipsagargin Demonstrates Clinical Benefit in Subset of Glioblastoma Patients GenSpera?s Interim Phase II Glioblastoma Data Showcased at Society for Neuro-Oncology Annual Meeting SAN ANTONIO, November 20, 2015 ? GenSpera Inc. (OTCQB: GNSZ), a biotech company developing a novel prodrug therapeutic for the treatment of cancer, today announced results from the Phase II study investigatin |
|
| November 17, 2015 |
Submission of Matters to a Vote of Security Holders 8-K 1 v4250348k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 17, 2015 (November 13, 2015) GENSPERA, INC. (Exact name of registrant as specified in Charter) Delaware 0001421204 20-0438951 (State or other jur |
|
| November 13, 2015 |
Exhibit 99.01 GenSpera Provides Update on Clinical Development Programs Upcoming Poster Presentation on Phase II Mipsagargin for the Treatment of Glioblastoma SAN ANTONIO (November 13, 2015) ? GenSpera, Inc. (OTC/QB: GNSZ), a biotech company developing a novel prodrug therapeutics for the treatment of cancer, is providing an update on its clinical development programs and corporate developments. T |
|
| November 13, 2015 |
Financial Statements and Exhibits, Other Events 8-K 1 v4247078k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 13, 2015 GENSPERA, INC. (Exact name of registrant as specified in Charter) Delaware 0001421204 20-0438951 (State or other jurisdiction of incorpo |
|
| November 13, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C.20549 FORM 10-Q 10-Q 1 v42381610q.htm FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C.20549 FORM 10-Q (Mark one) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2015 Or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 000-55331 GENSPERA |
|
| October 29, 2015 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 29, 2015 GENSPERA, INC. (Exact name of registrant as specified in Charter) Delaware 0001421204 20-0438951 (State or other jurisdiction of incorporation or organization) (Commi |
|
| October 29, 2015 |
World-renowned Neuro-oncologist Santosh Kesari, MD, PhD joins GenSpera’s Scientific Advisory Board EX-99.01 2 v423232ex99-01.htm EXHIBIT 99.01 Exhibit 99.01 World-renowned Neuro-oncologist Santosh Kesari, MD, PhD joins GenSpera’s Scientific Advisory Board SAN ANTONIO (October 29, 2015) – GenSpera, Inc. (OTC/QB: GNSZ), a San Antonio-based biotech company that develops innovative prodrug therapeutics for the treatment of cancer, announces that Santosh Kesari, MD, PhD, a board-certified neurologis |
|
| October 22, 2015 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 22, 2015 (October 21, 2015) GENSPERA, INC. (Exact name of registrant as specified in Charter) Delaware 0001421204 20-0438951 (State or other jurisdiction of incorporation or o |
|
| October 22, 2015 |
Exhibit 99.01 1 BIO Investor Forum October 21, 2015 OTC/QB : GNSZ www.GenSpera.com Craig A. Dionne, PhD President & CEO 2 Forward - Looking Statements Any statements that are not historical facts are forward - looking statements that involve risks and uncertainties that could cause actual results to differ materially from those in the forward - looking statements, which may include, but are not li |
|
| October 6, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) SCHEDULE 14A INFORMATION Proxy statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy statement o Confidential, for Use of the Commission Only (as permitted by Ru |
|
| September 25, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) SCHEDULE 14A INFORMATION Proxy statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: x Preliminary Proxy statement ? Confidential, for Use of the Commission Only (as permitted by Ru |
|
| September 9, 2015 |
Exhibit 99.02 IMMEDIATE RELEASE Media Relations: PCG Advisory Sean Leous +1-646-863-8998 [email protected] Investors Relations: PCG Advisory Adam Holdsworth +1-646-862-4607 [email protected] GenSpera Announces Encouraging Interim Phase II Data for Glioblastoma, Showcases Positive Future for Mipsagargin Across Multiple Types of Solid Tumors First-in Class Agent is Well Tolerated in Brain C |
|
| September 9, 2015 |
Exhibit 99.01 1 Rodman and Renshaw Presentation September 9, 2015 OTC QB : GNSZ Craig A. Dionne, PhD President & CEO 2 Safe Harbor Statement Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995: Any statements that are not historical facts are forward - looking statements that involve risks and uncertainties that could cause actual results to differ materially from thos |
|
| September 9, 2015 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 9, 2015 GENSPERA, INC. (Exact name of registrant as specified in Charter) Delaware 0001421204 20-0438951 (State or other jurisdiction of incorporation or organization) (Comm |
|
| September 4, 2015 |
Inspyr Therapeutics FORM 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 4, 2015 (September 2, 2015) GENSPERA, INC. (Exact name of registrant as specified in Charter) Delaware 0001421204 20-0438951 (State or other jurisdiction of incorporation or |
|
| August 19, 2015 |
18,555,308 Shares Common Stock Filed Pursuant to Rule 424b3 Registration No. 333-206242 PROSPECTUS 18,555,308 Shares Common Stock This prospectus relates to the resale of 18,555,308 shares of our common stock, by the selling stockholders identified in the selling stockholders tables beginning on page 13 of this prospectus (?Selling Stockholders?). We will not receive any proceeds from the sale of these shares by the Selling Sto |
|
| August 18, 2015 |
CORRESP 1 filename1.htm GENSPERA, INC. August 18, 2015 Jeffrey P. Riedler Assistant Director Division of Corporate Finance United States Securities and Exchange Commission Washington, DC 20549 RE: GenSpera, Inc. Registration Statement on Form S-1 Filed August 8, 2017 File No. 333-206242 Dear Mr. Riedler: We are in receipt of your letter dated August 17, 2015 advising us that the above referenced r |
|
| August 14, 2015 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 14, 2015 (August 12, 2015) GENSPERA, INC. (Exact name of registrant as specified in Charter) Delaware 0001421204 20-0438951 (State or other jurisdiction of incorporation or org |
|
| August 14, 2015 |
EX-99.01 2 v418319ex99-01.htm EXHIBIT 99.01 Exhibit 99.01 |
